Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats hypoparathyroidism. Sold as Yorvipath. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Palopegteriparatide (sold as Yorvipath), first approved Aug 9, 2024, with 0 new uses approved and 1 published complete response letter.
First approved: Aug 9, 2024
Applications: 1
New uses approved: 0
Complete response letters: 1
Medicare spending, 2025: $127M
Orphan exclusivity until: Aug 9, 2031
First approved in the EU: Nov 17, 2023
First approved in Japan: Aug 25, 2025
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
PalopegteriparatideProduct Quality / Device, Path Forward, Postmarketing Requirements Under 505(O)(3)
Approved
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA